Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18240 participants
INTERVENTIONAL
2015-06-30
2019-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Spatial Repellents for the Prevention of Malaria in Kenya
NCT04766879
Combating Dengue With Innovative, Paradigm-shift-Strategies: Early Dengue Surveillance in Adult Aedes Mosquitoes
NCT03799237
Targeted Chemo-elimination (TCE) of Malaria
NCT01872702
Efficacy and Safety of Ivermectin Against Dengue Infection
NCT02045069
Impact of Insecticide Resistance on Vector Control
NCT01713517
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators will establish a cohort of 3,400 persons, primarily children 2-12 years of age and adults who have not been previously infected with DCZV who will provide annual blood samples when they are healthy (longitudinal cohort), whereas in the same clusters the investigators expect to monitor up to 27,500 residents for active dengue disease (febrile surveillance cohort). The cohort will be monitored for a period of 2 years. The use of spatial repellents has never been tested on a large scale to reduce disease and could change vector control practices worldwide, reducing the amount of chemical insecticides applied and also prevent the development of insecticide resistance. The investigators plan to implement a short questionnaire to determine levels of acceptability and perceived efficacy amongst participating households.
The project will be carried out in the Amazonia City of Iquitos, Peru, which has a well-established infrastructure for studying urban dengue fever. The study will generate rigorous evidence, documenting and evaluating the impact of SR products on human infection rates, to be considered and used by academia, industry and public health key stakeholders at the global, regional, national and/or local level and drive efforts to acquire full recommendation of SR products for inclusion in disease control programs.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Transfluthrin
transfluthrin
transfluthrin
passive emanator with formulated transfluthrin
Placebo
inert ingredients
placebo
passive emanator with formulated inert ingredients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
transfluthrin
passive emanator with formulated transfluthrin
placebo
passive emanator with formulated inert ingredients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* plans to stay in study area for minimum of 12 months
* resident of household or frequent visitor (\~20% of day hours in house/mo)
* adult head of households agree to health visits and census
* individuals spend a minimum of 4hrs per week during the daytime hours or sleep in the house. Temporary residents can be included.
* individual who spends a minimum of 4 hours per week within the household
* ≥ 2 years of age
* fever at the time of presentation or report of feverishness within the previous 24 hours or presenting with a rash, arthralgia, arthritis or non-purulent conjunctivitis (suspicion of Zika determined by project physician)
\* adult head of households agrees to survey
\* adult head of households agrees to intervention deployment and to provide access to team member at 2-3 week intervals to change product
Exclusion Criteria
* temporary visitor to household
* plans to leave study area within next 12 months
FEBRILE SURVEILLANCE Household Level
* households where study personnel identify a security risk (i.e., site where drugs are sold, residents are always drunk or hostile)
* sites where no residents spend time during the day (i.e., work 7d a week outside the home)
FEBRILE SURVEILLANCE Individual Level
* \<2 years of age
* individuals who have spent less than 4 hours in the household during the week prior to illness
ENTOMOLOGICAL MONITORING Household Level
\* properties where study personnel identify a security risk (i.e., site where drugs are sold, residents are always drunk or hostile)
SPATIAL REPELLENT INTERVENTION Household Level
\* properties where study personnel identify a security risk (i.e., site where drugs are sold, residents are always drunk or hostile)
2 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Davis
OTHER
University of Notre Dame
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Davis
Iquitos, , Peru
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18-01-4370
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.